Edison Initiates Coverage on Photocure

Edison Investment Research, a leading international investment research firm, announces the initiation of full coverage of Photocure

News provided by

Edison Investment Research

Sep 25, 2015, 12:10 ET

LONDON, September 25, 2015 /PRNewswire/ --

Highlights of the analysis on Photocure by Edison's healthcare analysts Maxim Jacobs and Christian Glennie include:

Photocure specialises in photodynamic therapy. Its bladder cancer imaging product is sold as Hexvix in Europe and Cysview in the US. Photocure handles the marketing in Nordic countries and the US, while Ipsen is its marketing partner in the EU. Cevira is a Phase III-ready product for HPV-related diseases of the cervix and Visonac is a Phase III-ready product for acne.

(Logo: http://photos.prnewswire.com/prnh/20130417/608168 )

We value Photocure at NOK1,523m or NOK71 per basic share (NOK67 per diluted share). Upcoming catalysts will be the commencement of enrollment for the Phase III for Hexvix/Cysview to expand into the surveillance market and potential partnerships for both Visonac and Cevira.

To download this report, please click here.

All reports published by Edison are available to download free of charge from its website http://www.edisongroup.com.

About Edison: Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support their capital markets activities. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact:
Maxim Jacobs, Edison Investment Research, +1-646-653-7027
Christian Glennie, Edison Investment Research, +44-(0)20-3077-5727
[email protected]

Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:
LinkedIn http://www.linkedin.com/company/edison-investment-research
Twitter http://www.twitter.com/Edison_Inv_Res
YouTube http://www.youtube.com/edisonitv

SOURCE Edison Investment Research